Therefore, myostatin and NF-κB are probably implicated in skeletal muscle atrophy seen in PD and could be potentially targeted therapeutically to ameliorate skeletal muscle abnormalities characterizing PD. This evidence concerns the gene NFKB1 and Parkinson disease.